Annovis Bio provided a preliminary liquidity update for the third quarter of 2026, disclosing a restricted cash position as it finalizes its quarterly financial statements. The company has not yet completed its full closing process, and these estimates are subject to change upon the filing of the formal quarterly report.
Key Highlights
- Preliminary cash and cash equivalents were approximately $2.8 million as of September 30, 2026.
- Financial closing processes for the three and nine months ended September 30, 2026, remain ongoing and are not yet finalized.
- Reported figures are unaudited estimates and are not necessarily indicative of results for any future period.